Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men

Obi C. Umeh, Judith S. Currier, Jeong Gun Park, Yoninah Cramer, Ashwaq E. Hermes, Courtney V Fletcher

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The authors compared the pharmacokinetics of lopinavir (LPV) and ritonavir (RTV) between women and men. This 2-step, multicenter, pharmacokinetic study enrolled human immunodeficiency virus (HIV)-infected adults on lopinavir/ritonavir (LPV/r) capsules (400/100 mg bid) plus 1 or more nucleoside reverse transcriptase inhibitors. All participants underwent 12-hour pharmacokinetic sampling. The pharmacokinetic sampling was repeated in participants receiving the LPV/r tablet formulation. Step 1 enrolled 37 women and 40 men; step 2 included 42 participants from step 1 plus 35 new participants (39 women and 38 men). LPV pharmacokinetics in women and men were not significantly different with either formulation. Women had significantly higher median RTV AUC0-12 h with both the soft-gel capsule (SGC) and tablet formulations (SGC: 5395 vs 4119 ng•h/mL, P =.026; tablet: 5310 vs 3941 ng•h/mL, P =.012), higher median Cmax (SGC: 802 vs 635 ng/mL, P =.032; tablet: 773 vs 570 ng/mL, P =.006), and lower median CL/F (SGC: 18.54 vs 24.31 L/h, P =.026; tablet: 18.83 vs 25.37 L/h, P =.012). RTV CL/F was slower in women after weight adjustment with both formulations. The pharmacokinetics of LPV in the SGC and tablet formulations are comparable in HIV-infected patients. Women had higher RTV AUC0-12 h and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation.

Original languageEnglish (US)
Pages (from-to)1665-1673
Number of pages9
JournalJournal of Clinical Pharmacology
Volume51
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

Lopinavir
Ritonavir
Sex Characteristics
Tablets
Pharmacokinetics
Capsules
HIV
Gels
Reverse Transcriptase Inhibitors
Nucleosides
Multicenter Studies
Weights and Measures

Keywords

  • HIV infection
  • lopinavir/ritonavir
  • pharmacokinetics
  • sex differences

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. / Umeh, Obi C.; Currier, Judith S.; Park, Jeong Gun; Cramer, Yoninah; Hermes, Ashwaq E.; Fletcher, Courtney V.

In: Journal of Clinical Pharmacology, Vol. 51, No. 12, 01.12.2011, p. 1665-1673.

Research output: Contribution to journalArticle

Umeh, Obi C. ; Currier, Judith S. ; Park, Jeong Gun ; Cramer, Yoninah ; Hermes, Ashwaq E. ; Fletcher, Courtney V. / Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. In: Journal of Clinical Pharmacology. 2011 ; Vol. 51, No. 12. pp. 1665-1673.
@article{940e5a61e2bd46b3b9e27e5bc18084a2,
title = "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men",
abstract = "The authors compared the pharmacokinetics of lopinavir (LPV) and ritonavir (RTV) between women and men. This 2-step, multicenter, pharmacokinetic study enrolled human immunodeficiency virus (HIV)-infected adults on lopinavir/ritonavir (LPV/r) capsules (400/100 mg bid) plus 1 or more nucleoside reverse transcriptase inhibitors. All participants underwent 12-hour pharmacokinetic sampling. The pharmacokinetic sampling was repeated in participants receiving the LPV/r tablet formulation. Step 1 enrolled 37 women and 40 men; step 2 included 42 participants from step 1 plus 35 new participants (39 women and 38 men). LPV pharmacokinetics in women and men were not significantly different with either formulation. Women had significantly higher median RTV AUC0-12 h with both the soft-gel capsule (SGC) and tablet formulations (SGC: 5395 vs 4119 ng•h/mL, P =.026; tablet: 5310 vs 3941 ng•h/mL, P =.012), higher median Cmax (SGC: 802 vs 635 ng/mL, P =.032; tablet: 773 vs 570 ng/mL, P =.006), and lower median CL/F (SGC: 18.54 vs 24.31 L/h, P =.026; tablet: 18.83 vs 25.37 L/h, P =.012). RTV CL/F was slower in women after weight adjustment with both formulations. The pharmacokinetics of LPV in the SGC and tablet formulations are comparable in HIV-infected patients. Women had higher RTV AUC0-12 h and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation.",
keywords = "HIV infection, lopinavir/ritonavir, pharmacokinetics, sex differences",
author = "Umeh, {Obi C.} and Currier, {Judith S.} and Park, {Jeong Gun} and Yoninah Cramer and Hermes, {Ashwaq E.} and Fletcher, {Courtney V}",
year = "2011",
month = "12",
day = "1",
doi = "10.1177/0091270010388650",
language = "English (US)",
volume = "51",
pages = "1665--1673",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "12",

}

TY - JOUR

T1 - Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men

AU - Umeh, Obi C.

AU - Currier, Judith S.

AU - Park, Jeong Gun

AU - Cramer, Yoninah

AU - Hermes, Ashwaq E.

AU - Fletcher, Courtney V

PY - 2011/12/1

Y1 - 2011/12/1

N2 - The authors compared the pharmacokinetics of lopinavir (LPV) and ritonavir (RTV) between women and men. This 2-step, multicenter, pharmacokinetic study enrolled human immunodeficiency virus (HIV)-infected adults on lopinavir/ritonavir (LPV/r) capsules (400/100 mg bid) plus 1 or more nucleoside reverse transcriptase inhibitors. All participants underwent 12-hour pharmacokinetic sampling. The pharmacokinetic sampling was repeated in participants receiving the LPV/r tablet formulation. Step 1 enrolled 37 women and 40 men; step 2 included 42 participants from step 1 plus 35 new participants (39 women and 38 men). LPV pharmacokinetics in women and men were not significantly different with either formulation. Women had significantly higher median RTV AUC0-12 h with both the soft-gel capsule (SGC) and tablet formulations (SGC: 5395 vs 4119 ng•h/mL, P =.026; tablet: 5310 vs 3941 ng•h/mL, P =.012), higher median Cmax (SGC: 802 vs 635 ng/mL, P =.032; tablet: 773 vs 570 ng/mL, P =.006), and lower median CL/F (SGC: 18.54 vs 24.31 L/h, P =.026; tablet: 18.83 vs 25.37 L/h, P =.012). RTV CL/F was slower in women after weight adjustment with both formulations. The pharmacokinetics of LPV in the SGC and tablet formulations are comparable in HIV-infected patients. Women had higher RTV AUC0-12 h and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation.

AB - The authors compared the pharmacokinetics of lopinavir (LPV) and ritonavir (RTV) between women and men. This 2-step, multicenter, pharmacokinetic study enrolled human immunodeficiency virus (HIV)-infected adults on lopinavir/ritonavir (LPV/r) capsules (400/100 mg bid) plus 1 or more nucleoside reverse transcriptase inhibitors. All participants underwent 12-hour pharmacokinetic sampling. The pharmacokinetic sampling was repeated in participants receiving the LPV/r tablet formulation. Step 1 enrolled 37 women and 40 men; step 2 included 42 participants from step 1 plus 35 new participants (39 women and 38 men). LPV pharmacokinetics in women and men were not significantly different with either formulation. Women had significantly higher median RTV AUC0-12 h with both the soft-gel capsule (SGC) and tablet formulations (SGC: 5395 vs 4119 ng•h/mL, P =.026; tablet: 5310 vs 3941 ng•h/mL, P =.012), higher median Cmax (SGC: 802 vs 635 ng/mL, P =.032; tablet: 773 vs 570 ng/mL, P =.006), and lower median CL/F (SGC: 18.54 vs 24.31 L/h, P =.026; tablet: 18.83 vs 25.37 L/h, P =.012). RTV CL/F was slower in women after weight adjustment with both formulations. The pharmacokinetics of LPV in the SGC and tablet formulations are comparable in HIV-infected patients. Women had higher RTV AUC0-12 h and lower CL/F with both formulations. The mechanism of the sex difference in RTV CL/F warrants elucidation.

KW - HIV infection

KW - lopinavir/ritonavir

KW - pharmacokinetics

KW - sex differences

UR - http://www.scopus.com/inward/record.url?scp=79959216019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959216019&partnerID=8YFLogxK

U2 - 10.1177/0091270010388650

DO - 10.1177/0091270010388650

M3 - Article

C2 - 21233301

AN - SCOPUS:79959216019

VL - 51

SP - 1665

EP - 1673

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 12

ER -